Thai Trial – HIV vaccine effort
New hope for HIV vaccination
The US Military HIV Research Program announced on Sept 24 the top-line results from a large trial of a vaccine candidate conducted in Thailand (https://www01.hjf.org/apps/internet/hivnewscenter.nsf/phase3). The vaccine candidate contained two ingredients, one intended to induce T cell immunity and the second intended to induce neutralizing antibodies The two ingredients tested individually in previous trials did not reduce the risk of HIV infection. In the two-ingredient vaccine trial, of 8,197 trial subjects who received the vaccine candidate, 51 contracted HIV infection over a 3 year follow-up period. In comparison, of 8,198 trial subjects who did not receive the vaccine candidate (placebo recipients), 74 contracted the infection. This represents a statistically significant reduction of infection risk (31.2% risk reduction; P<0.04). CIF applauds the modest success of this vaccine candidate as an incremental milestone. CIF recognizes, however, that a more effective vaccine is necessary to prevent the spread of HIV infection, and it is committed to helping develop innovative vaccine candidates.
Advertisement
